Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study on Using TROP2-PET and 18F-FDG PET to Predict the Efficacy of Anti TROP2 ADC Treatment in Advanced Breast Cancer
Sponsor: Fudan University
Summary
This study aims to evaluate whether \^68Ga-TROP2 PET/CT, combined with \^18F-FDG PET/CT, can predict the efficacy of anti-TROP2 antibody-drug conjugates in patients with advanced HER2-negative breast cancer. Baseline and dynamic imaging parameters will be used to develop prediction models (primary endpoint: AUC), and their associations with clinical outcomes and tumor TROP2 status will be explored.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
45
Start Date
2026-03-11
Completion Date
2029-03-11
Last Updated
2026-03-13
Healthy Volunteers
No
Interventions
Sacituzumab Govitecan、Datopotamab deruxtecan、Sacituzumab tirumotecan
TROP2-targeted antibody-drug conjugate administered according to standard clinical dosing schedule until disease progression or unacceptable toxicity.
68Ga-TROP2 PET/CT Imaging
Whole-body PET imaging using 68Ga-labeled TROP2-targeting tracer to assess in vivo TROP2 expression prior to TROP2 ADC treatment initiation.
18F-FDG PET Imaging
Standard 18F-FDG PET imaging performed prior to TROP2 ADC treatment to assess tumor metabolic activity.
Locations (2)
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China
Fudan University Shanghai Cancer Center
Shanghai, China